Pfizer Inc. and BioNTech SE announced on Tuesday the start of a clinical study that aims to determine "the safety, tolerability and immunogenicity" of a jointly-developed vaccine targeting the Omicron coronavirus variant, APA reports citing Teletrader.
The companies explained that the study will cover 1,420 healthy adults aged 18-55, divided into three groups based on different vaccine regimens including their standard coronavirus shot and their Omicron-specific vaccine.
"This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but with longer duration of protection," BioNTech CEO and co-founder Ugur Sahin said in the press release.
Follow us on Telegram
t.me/apanewsaz
Follow us on Instagram
Follow us on TikTok
Follow us on Facebook
Follow us on X
